Dr. Brian Samuel Henick, MD

Dr. Henick practices at Columbia University Irving Medical Center in New York, New York.

Dr. Henick's NPI, 1316212533, was assigned on March 21, 2012. Dr. Henick graduated from Rutgers New Jersey Medical School in 2012. Dr. Henick holds New York license 293244.

Dr. Henick's primary practice is Columbia University Irving Medical Center, at 622 W 168th St, New York, NY 10032 in New York County. The practice phone is (212) 297-4255.

Dr. Henick's primary practice is Columbia University Irving Medical Center in New York, New York. Dr. Henick is also affiliated with NewYork-Presbyterian/Weill Cornell Medical Center. The medical group on file is ColumbiaDoctors. Dmand AI also links Dr. Henick to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Henick practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Henick's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Henick is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Henick's licenses on file in 2 states: New York and Connecticut.

Dmand AI lists fluid and electrolyte imbalances and lung cancer among the conditions Dr. Henick treats.

CMS data shows 596 Medicare services from Dr. Henick across 4 procedure codes in 2024, for 124 Medicare patients. Medicare paid $50,401 for them. Every service was in an office.

CMS counts 124 Medicare patients who saw Dr. Henick in 2024. The largest group is 75 to 84, with 56 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 28% are also on Medicaid. Their average risk score is 3.16, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Henick's median patient age at 72, with 41% women.

In 2024, Dr. Henick wrote 51 Medicare Part D claims for 24 patients. 92% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $171 in total drug cost. In 2023, CMS named 45 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Henick for performance year 2024, reported through an alternative payment model (APM). Dr. Henick accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Henick as offering telehealth.

Dmand AI links 41 papers to Dr. Henick, published from 2011 to 2025. 2023 was the busiest year, with 6. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Immunotherapy. Dr. Henick has published most often in JCO Precis Oncol. Dr. Henick's most frequent co-authors are Naiyer A. Rizvi, MD, Catherine Ann Shu and Mark M. Awad, MD, PhD.

Dmand AI links Dr. Henick to 10 clinical trials, 6 of them phase 2 studies. 4 are still active or recruiting. Conditions studied include Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung and Small Cell Lung Carcinoma. Columbia University sponsors the most, 2.

CMS Open Payments shows 42 general payments to Dr. Henick from 12 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 91% of the total. Jazz Pharmaceuticals Inc. paid the most, $8,480. It also lists 2 research payments totaling $188 in 2024.

Dr. Henick graduated from Rutgers New Jersey Medical School in 2012.

Dr. Henick is in network with 12 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.